DSGN vs. SNDX, COLL, ALVR, SYRE, ELVN, GYRE, ADPT, NTLA, ZYME, and RCKT
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), AlloVir (ALVR), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Gyre Therapeutics (GYRE), Adaptive Biotechnologies (ADPT), Intellia Therapeutics (NTLA), Zymeworks (ZYME), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry.
Design Therapeutics vs.
Design Therapeutics (NASDAQ:DSGN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
Design Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 40.42%. Syndax Pharmaceuticals has a consensus price target of $36.20, indicating a potential upside of 161.94%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Design Therapeutics.
In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Syndax Pharmaceuticals and 3 mentions for Design Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 0.71 beat Design Therapeutics' score of 0.66 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
Design Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
Design Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Design Therapeutics' return on equity of -18.01% beat Syndax Pharmaceuticals' return on equity.
56.6% of Design Therapeutics shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Syndax Pharmaceuticals received 377 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 65.37% of users gave Syndax Pharmaceuticals an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote.
Summary
Syndax Pharmaceuticals beats Design Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DSGN) was last updated on 1/23/2025 by MarketBeat.com Staff
